ATE424842T1 - Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten - Google Patents
Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatientenInfo
- Publication number
- ATE424842T1 ATE424842T1 AT04797460T AT04797460T ATE424842T1 AT E424842 T1 ATE424842 T1 AT E424842T1 AT 04797460 T AT04797460 T AT 04797460T AT 04797460 T AT04797460 T AT 04797460T AT E424842 T1 ATE424842 T1 AT E424842T1
- Authority
- AT
- Austria
- Prior art keywords
- fragments
- bcl
- cancer patients
- family proteins
- proteins
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title abstract 2
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 title 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 102000007079 Peptide Fragments Human genes 0.000 abstract 2
- 108010033276 Peptide Fragments Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000051485 Bcl-2 family Human genes 0.000 abstract 1
- 108700038897 Bcl-2 family Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52311903P | 2003-11-19 | 2003-11-19 | |
| DKPA200301716 | 2003-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE424842T1 true ATE424842T1 (de) | 2009-03-15 |
Family
ID=39149116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04797460T ATE424842T1 (de) | 2003-11-19 | 2004-11-18 | Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7842294B2 (de) |
| EP (2) | EP1691824B1 (de) |
| JP (2) | JP4926714B2 (de) |
| KR (2) | KR101284237B1 (de) |
| CN (1) | CN1921878B (de) |
| AT (1) | ATE424842T1 (de) |
| AU (1) | AU2004290866B2 (de) |
| CA (1) | CA2546794C (de) |
| DE (1) | DE602004019965D1 (de) |
| DK (2) | DK2087904T3 (de) |
| ES (2) | ES2323588T3 (de) |
| HK (1) | HK1101131A1 (de) |
| MX (1) | MXPA06005738A (de) |
| PL (2) | PL2087904T3 (de) |
| PT (1) | PT1691824E (de) |
| RU (1) | RU2367468C2 (de) |
| WO (1) | WO2005049073A2 (de) |
| ZA (1) | ZA200604866B (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| CN103288920B (zh) * | 2003-01-30 | 2015-08-12 | 苏瓦克有限公司 | 存活蛋白衍生肽及其用途 |
| WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
| WO2006045076A2 (en) * | 2004-10-19 | 2006-04-27 | Massachusetts Institute Of Technology | Virus scaffold for self-assembled, flexible and light lithium battery |
| AU2011203535B2 (en) * | 2005-02-04 | 2012-10-11 | Survac Aps | Survivin peptide vaccine |
| AU2006209951B2 (en) * | 2005-02-04 | 2011-04-14 | Survac Aps | Survivin peptide vaccine |
| CA2622504A1 (en) * | 2005-09-09 | 2008-03-08 | Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for inhibiting cell death or enhancing cel proliferation |
| WO2008116468A2 (en) * | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
| EP2167537A2 (de) | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Zusammengestellte verfahren für die analyse und sortierung von proben |
| EP2197908A2 (de) * | 2007-09-27 | 2010-06-23 | Dako Denmark A/S | Mhc-multimere in tuberkulose-diagnostika, -impfstoff und therapeutika |
| US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
| EP2254592B1 (de) * | 2008-02-28 | 2019-06-05 | Dako Denmark A/S | Mhc-multimere in borrelia-diagnostika und erkrankungen |
| US8986702B2 (en) | 2008-05-16 | 2015-03-24 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| CA2730369A1 (en) * | 2008-07-16 | 2010-01-21 | Burnham Institute For Medical Research | Compositions and methods for modulating nod-like receptor activity and uses thereof |
| US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
| EP2318435B1 (de) | 2008-08-28 | 2015-12-23 | Taiga Biotechnologies, Inc. | Myc-modulatoren, verfahren zu ihrer verwendung und verfahren zur identifikation von mitteln zur myc-modulierung |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| WO2010037397A1 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cmv immune monitoring |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| AU2009305617B2 (en) | 2008-10-17 | 2014-01-23 | University Of Miami | Tumor vaccine |
| EP3444333A1 (de) * | 2009-10-22 | 2019-02-20 | Thomas Jefferson University | Zellbasierte antikrebszusammensetzungen sowie verfahren zur herstellung und verwendung davon |
| BR112012022641A2 (pt) | 2010-03-11 | 2017-02-14 | Oncotherapy Science Inc | peptídeos hjurp e vacinas que incluem os mesmos |
| EP2608799B1 (de) * | 2010-08-24 | 2018-12-12 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Impfstoffe gegen hirntumore auf interleukin-13-rezeptor-alpha 2-peptid-basis |
| EP4321218A3 (de) | 2012-05-16 | 2024-04-24 | Stemline Therapeutics, Inc. | Auf krebsstammzellen zielende krebsimpfstoffe |
| EP2877189B1 (de) * | 2012-07-20 | 2021-01-06 | Taiga Biotechnologies, Inc. | Verbesserte rekonstitution und autorekonstitution des hämatopoietischen kompartments |
| EP2961419A4 (de) * | 2013-02-26 | 2016-12-21 | Rongfu Wang | Phf20- und jmjd3-zusammensetzungen und verfahren zur verwendung in der krebsimmuntherapie |
| EP2961415B1 (de) * | 2013-03-01 | 2021-01-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Verfahren zur herstellung angereicherte populationen tumorreaktiver t-zellen aus einem tumor |
| US9704181B2 (en) * | 2014-05-06 | 2017-07-11 | International Business Machines Corporation | Real-time social group based bidding system |
| CA3045017A1 (en) | 2016-12-02 | 2018-06-07 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| RS64217B1 (sr) * | 2017-01-27 | 2023-06-30 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raka jajnika i drugih malignih tumora |
| WO2018138257A1 (en) * | 2017-01-27 | 2018-08-02 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| AR110857A1 (es) | 2017-01-27 | 2019-05-08 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
| CA3110760A1 (en) | 2018-09-04 | 2020-03-12 | Treos Bio Limited | Peptide vaccines |
| CN113355432A (zh) * | 2021-05-12 | 2021-09-07 | 甘肃农业大学 | Bmf作为细胞凋亡标志物的应用 |
| WO2022245249A1 (ru) * | 2021-05-17 | 2022-11-24 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) | Пептидные соединения для индукции апоптоза в опухолевой клетке |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
| WO1994005304A1 (en) | 1992-08-31 | 1994-03-17 | Ludwig Institute For Cancer Research | Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof |
| US5470955A (en) | 1993-02-02 | 1995-11-28 | Dartmouth College | Antibodies which specifically bind mcl-1 polypeptide |
| US5646008A (en) * | 1993-06-22 | 1997-07-08 | The Regent Of The University Of Michigan | Vertebrate apoptosis gene: compositions and methods |
| US5700638A (en) * | 1993-08-26 | 1997-12-23 | Washington University | Cell death regulator |
| GB9320597D0 (en) | 1993-10-06 | 1993-11-24 | Proteus Molecular Design | Improvements in and realting to vaccines |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| US5789201A (en) * | 1996-02-23 | 1998-08-04 | Cocensys, Inc. | Genes coding for bcl-y a bcl-2 homologue |
| KR100645448B1 (ko) | 1996-11-20 | 2006-11-13 | 예일 유니버시티 | 세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법 |
| WO1998058541A1 (en) | 1997-06-24 | 1998-12-30 | Dana-Farber Cancer Institute, Inc. | Modulation of apoptosis |
| WO2001036594A1 (en) | 1999-11-16 | 2001-05-25 | Dartmouth College | Mcl-1 GENE REGULATORY ELEMENTS AND A PRO-APOPTOTIC Mcl-1 VARIANT |
| EP1238080A2 (de) | 1999-12-14 | 2002-09-11 | The Burnham Institute | Bcl-g polypeptide, kodierende nukleine säuren und verfahren zur anwendungen |
| WO2002005835A2 (en) | 2000-07-17 | 2002-01-24 | Washington University | Modulation of apoptosis |
| AU2002257647A1 (en) * | 2001-03-09 | 2002-09-24 | Callistogen Ag | Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination |
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| PL1618130T3 (pl) | 2003-04-11 | 2013-08-30 | Survac Aps | Szczepionka terapeutyczna przeciw nowotworom |
-
2004
- 2004-11-18 EP EP04797460A patent/EP1691824B1/de active Active
- 2004-11-18 MX MXPA06005738A patent/MXPA06005738A/es active IP Right Grant
- 2004-11-18 JP JP2006540170A patent/JP4926714B2/ja active Active
- 2004-11-18 DE DE602004019965T patent/DE602004019965D1/de active Active
- 2004-11-18 DK DK09154734.9T patent/DK2087904T3/da active
- 2004-11-18 US US10/580,016 patent/US7842294B2/en active Active
- 2004-11-18 WO PCT/DK2004/000799 patent/WO2005049073A2/en active Application Filing
- 2004-11-18 PL PL09154734T patent/PL2087904T3/pl unknown
- 2004-11-18 AU AU2004290866A patent/AU2004290866B2/en active Active
- 2004-11-18 KR KR1020127016885A patent/KR101284237B1/ko active IP Right Grant
- 2004-11-18 KR KR1020067012186A patent/KR101216655B1/ko active IP Right Grant
- 2004-11-18 ZA ZA200604866A patent/ZA200604866B/en unknown
- 2004-11-18 ES ES04797460T patent/ES2323588T3/es active Active
- 2004-11-18 RU RU2006121466/15A patent/RU2367468C2/ru active
- 2004-11-18 CN CN2004800407050A patent/CN1921878B/zh active Active
- 2004-11-18 PT PT04797460T patent/PT1691824E/pt unknown
- 2004-11-18 DK DK04797460T patent/DK1691824T3/da active
- 2004-11-18 PL PL04797460T patent/PL1691824T3/pl unknown
- 2004-11-18 AT AT04797460T patent/ATE424842T1/de active
- 2004-11-18 EP EP09154734.9A patent/EP2087904B1/de active Active
- 2004-11-18 ES ES09154734.9T patent/ES2436429T3/es active Active
- 2004-11-18 CA CA2546794A patent/CA2546794C/en active Active
-
2007
- 2007-08-23 HK HK07109167.1A patent/HK1101131A1/xx unknown
-
2011
- 2011-09-12 JP JP2011198605A patent/JP5502823B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE424842T1 (de) | Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten | |
| CY1119127T1 (el) | Επιτοποι σκληροστινης | |
| ATE486087T1 (de) | Fgf-5-bindende und geträgerte peptide | |
| CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
| CA2523467C (en) | Treatment of t-cell mediated diseases | |
| MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
| DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
| WO2007034489A3 (en) | Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom | |
| DE60032486D1 (de) | Prion protein peptide und deren verwendung | |
| DK1545613T3 (da) | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom | |
| EP2182006A3 (de) | Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen | |
| NO20045521L (no) | Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer | |
| CY1118930T1 (el) | Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων | |
| ATE549353T1 (de) | Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen | |
| EA200801411A1 (ru) | Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях | |
| DE60230456D1 (de) | Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren | |
| ATE551069T1 (de) | Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung | |
| WO2006137938A3 (en) | Antibody fragments for protection from pathogen infection and methods of use thereof | |
| NO20060781L (no) | Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser | |
| WO2001007479A3 (en) | Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases | |
| ATE467421T1 (de) | Cytokine und cytokinrezeptoren mit reduzierter immunogenität | |
| WO2006110881A3 (en) | Yersinia polypeptide vaccines, antibodies and immunomodulatory proteins | |
| ATE505538T1 (de) | Dna-vektoren | |
| CY1108761T1 (el) | Απενεργοποιημενες κυτοκινες για ανοσοποιηση | |
| DE60229924D1 (de) | Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1691824 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |